A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)

Next Previous
Trial Profile

A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects With Dementia With Lewy Bodies (DLB)

Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Intepirdine (Primary)
  • Indications Dementia; Lewy body disease
  • Focus Adverse reactions
  • Acronyms HEADWAY-DLB Extension
  • Sponsors Axovant Sciences

    • Most Recent Events

    • 13 Feb 2018 Status changed from recruiting to discontinued.
    • 28 Jul 2017 Planned End Date changed from 1 Mar 2018 to 1 Nov 2018.
    • 28 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top